Prof Jeffrey Cummings

Professor Cummings is a world-renowned Alzheimer’s researcher and leader of clinical trials.  He has been recognized for his research and leadership contributions in the field of Alzheimer’s disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer’s Association (2008), and the Lifetime Achievement Award of the Society for Behavioural and Cognitive Neurology (2017). In 2010, he was honoured by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award.  In 2018, he was honoured with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer’s Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer’s Drug Discovery Foundation’s Melvin R. Goodes Prize that honours an innovative researcher who has made a significant and lasting impact in the field.

Professor Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society.

Professor Cummings has authored or edited 43 books and published over 750 peer-reviewed papers.

Jeffrey L. Cummings, MD, ScD, is Vice Chair of Research, UNLV Department of Brain Health. He is Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada, and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Dr. Cummings is Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience.

Prof Colin Masters AO

Professor Masters’ research career in Alzheimer’s disease and other neurodegenerative diseases spans over 35 years. He is widely acknowledged as a major worldwide influencer on Alzheimer’s disease research and our understanding of what causes the disease. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary step for therapeutic intervention.

Professor Masters is a driving force behind the Australian Imaging, Biomarkers & Lifestyle (AIBL) study to determine which biomarkers, cognitive characteristics, and health and lifestyle factors determine subsequent development of Alzheimer’s.

Professor Masters is the Laureate Professor of Dementia Research and Head, Neurodegeneration Division at The Florey Institute, The University of Melbourne and a consultant at the Royal Melbourne Hospital.

Prof Craig Ritchie (Chair)

Professor Ritchie is a world-leading authority on dementia and has been a senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. Professor Ritchie is leading the PREVENT project to identify mid-life risks for dementia, and the European Prevention of Alzheimer’s Dementia (EPAD) Consortium, to understand early aspects of Alzheimer’s disease before dementia develops.

Professor Ritchie has extensive knowledge of the pharmaceutical industry, having sat on advisory boards of numerous pharmaceutical companies, biotechnology companies, and clinical research organizations, all with an interest in developing drugs and clinical trials for Alzheimer’s disease. Professor Ritchie is the Chair of the Scottish Dementia Research Consortium, Professor of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention at the University of Edinburgh, Associate Director of the Wellcome Trust Clinical Research Facility and Co Coordinator at IMI-EPAD.